Day: June 24, 2022

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 daysIf approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG)Breda, the Netherlands—June 24, 2022—argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of efgartigimod as an add-on...

Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti Paris, France, June 24, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the appointment of Anja Krammer and August Moretti as members of the company’s Board of Directors. Ms. Krammer is an entrepreneur and global business leader who has co-founded several startups and has extensive experience in driving strategy and implementation in healthcare and technology companies. Mr. Moretti is a seasoned financial executive who has raised almost two billion US dollars in capital and has completed 54 quarters of SEC reporting as Chief...

Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccinePrimary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19 Against Omicron, sequencing analysis performed to date shows 72% efficacy in all adults and 93.2% in seropositives Favorable safety and tolerability profile First ever reported efficacy data in an Omicron environment support relevance of a Beta-containing vaccineParis, June 24, 2022. Sanofi and GSK today announce positive data from their vaccine trial which evaluated an adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an...

Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s license partner, Pfizer Inc. Intravenous use of Cresemba approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis following previous approval of oral dosage formBasel/Allschwil, Switzerland, June 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its license partner, Pfizer Inc. (NYSE: PFE, “Pfizer”), has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the intravenous formulation of Cresemba® (isavuconazole) for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. This is the second approved formulation for Cresemba in China, in addition to...

Saint–Herblain (France), June 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held yesterday in Paris. Among the adopted resolutions were approval of the 2021 financial statements, delegations for the management board to increase Valneva’s share capital and/or issue financial instruments, and the appointment, for a three-year term, of two new Supervisory Board members. Bpifrance Participations was appointed to Valneva’s Supervisor Board and will be represented by Maïlys Ferrère. Ms. Ferrère, a French national, is Director of Large Venture Investments at Bpifrance, France’s state-owned investment bank. In her role at Bpifrance, she sits on various...

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Ms. Windels has been a member of the Board of Directors since May 2018. Ms. Windels serves on multiple boards in the life sciences industry and has been an executive in the sector from 1999 through 2021, serving primarily as Chief Financial Officer and, over the last five years, as Chief Executive Officer. Ms. Windels succeeds Michel Lussier who has been named Interim Chief Executive Officer of the Company, effective immediately....

CALGARY, Alberta, June 23, 2022 (GLOBE NEWSWIRE) — The annual and special meeting of shareholders (the “Meeting”) of CE Brands Inc. (TSXV: CEBI; CEBI.WT) (“CE Brands”, “we”, “our”, or the “Company”), a data-driven consumer-electronics company, was held earlier today via live audio and slideshow webcast. Each of the matters voted upon at the Meeting is discussed in detail in the Company’s management information circular dated May 12, 2022 (the “Circular”), which can be found under the Company’s profile on SEDAR at www.sedar.com. The total number of votes cast by shareholders in person or by proxy at the Meeting was 7,612,677 votes (including votes cast in respect of proxies received following the proxy cutoff time, which the Company determined to waive to permit additional votes cast by shareholders to be included in the voting...

Highlights:Headcount reduction by 40% resulting in over $4m in cost savings per year Agreement to sell non-core asset for aggregate gross proceeds of $3.4mTORONTO, June 23, 2022 (GLOBE NEWSWIRE) — The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) herein announces the completion of a significant corporate headcount reduction resulting in over $4m in cost savings per year as well as an agreement to sell a non-core asset for aggregate gross proceeds of $3.4m. Headcount Reduction The Company has completed a headcount reduction necessary in order to flatten its organizational structure and right-size SG&A with revenue. The Company has eliminated 40% of its workforce, largely in senior and middle management, resulting in an anticipated annual savings of over $4m. Agreement to Sell Flowr Forest The Company...